URGNUroGen Pharma Ltd.
$36.82+105% 1Y
$36.82
$16.4252 weeks$50.29
The financials
UroGen Pharma Ltd. by the numbers
UroGen Pharma Ltd. (URGN) reported revenue of $72M in Q2 2026 (quarter ended Jun 30, 2026), up 199% from the same quarter a year earlier. That came with a gross margin of 91% and net loss of $14M. For the full year FY2025, revenue was $110M (+21% year on year) and net income −$153M. Its largest product in Q2 2026 was Zusduri at $50M, 70% of the disclosed total, well ahead of Jelmyto at 30%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $72M | $24M | +199% |
| Gross profit | $66M | $21M | +219% |
| Operating income | $111K | −$41M | to a profit |
| Net income | −$14M | −$50M | n/a |
| Product | Revenue | Share |
|---|---|---|
| Zusduri | $50M | 70% |
| Jelmyto | $22M | 30% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $72.5M (+42%)
Jelmyto grew -9.0% year on year
Segment Latestquarter on quarteryear on year
- Zusduri$50.4M$50.4Mquarter on quarter +72%year on year n/a+72%n/a
- Jelmyto$22.0M$22.0Mquarter on quarter +1.5%year on year -9.0%+1.5%-9.0%
On our screens:Most shorted stocks